KR20150132092A - 나이브한 대상들을 위한 백신 조성물 - Google Patents

나이브한 대상들을 위한 백신 조성물 Download PDF

Info

Publication number
KR20150132092A
KR20150132092A KR1020157019558A KR20157019558A KR20150132092A KR 20150132092 A KR20150132092 A KR 20150132092A KR 1020157019558 A KR1020157019558 A KR 1020157019558A KR 20157019558 A KR20157019558 A KR 20157019558A KR 20150132092 A KR20150132092 A KR 20150132092A
Authority
KR
South Korea
Prior art keywords
acid
vaccine
composition
influenza
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020157019558A
Other languages
English (en)
Korean (ko)
Inventor
한스 아르비손
안나-카린 말타이스
Original Assignee
유로씨네 백신즈 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유로씨네 백신즈 에이비 filed Critical 유로씨네 백신즈 에이비
Publication of KR20150132092A publication Critical patent/KR20150132092A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020157019558A 2012-12-17 2013-12-17 나이브한 대상들을 위한 백신 조성물 Ceased KR20150132092A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12197522.1 2012-12-17
EP12197522.1A EP2742952A1 (en) 2012-12-17 2012-12-17 Influenza vaccine composition
PCT/EP2013/077006 WO2014095943A1 (en) 2012-12-17 2013-12-17 Vaccine composition for naive subjects

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217000812A Division KR20210007042A (ko) 2012-12-17 2013-12-17 나이브한 대상들을 위한 백신 조성물

Publications (1)

Publication Number Publication Date
KR20150132092A true KR20150132092A (ko) 2015-11-25

Family

ID=47358019

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020157019558A Ceased KR20150132092A (ko) 2012-12-17 2013-12-17 나이브한 대상들을 위한 백신 조성물
KR1020157019562A Ceased KR20150132093A (ko) 2012-12-17 2013-12-17 면역손상된 인구들에서의 사용을 위한 백신 조성물
KR1020217000812A Ceased KR20210007042A (ko) 2012-12-17 2013-12-17 나이브한 대상들을 위한 백신 조성물

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020157019562A Ceased KR20150132093A (ko) 2012-12-17 2013-12-17 면역손상된 인구들에서의 사용을 위한 백신 조성물
KR1020217000812A Ceased KR20210007042A (ko) 2012-12-17 2013-12-17 나이브한 대상들을 위한 백신 조성물

Country Status (12)

Country Link
US (2) US20150306204A1 (enExample)
EP (4) EP2742952A1 (enExample)
JP (3) JP2016502997A (enExample)
KR (3) KR20150132092A (enExample)
CN (3) CN104884085A (enExample)
AU (2) AU2013360889C1 (enExample)
BR (2) BR112015014174A2 (enExample)
CA (2) CA2895023A1 (enExample)
HK (2) HK1212611A1 (enExample)
MX (2) MX2015007688A (enExample)
RU (2) RU2661408C2 (enExample)
WO (2) WO2014095943A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2621524A1 (en) * 2010-09-30 2013-08-07 Eurocine Vaccines AB Improved vaccine compositions
AU2015323334B2 (en) * 2014-09-26 2021-02-25 Seqirus UK Limited Vaccination of immunocompromised subjects
HUE060456T2 (hu) * 2014-09-26 2023-03-28 Seqirus Uk Ltd Immunkompromittált alanyok oltása
RU2634247C2 (ru) * 2015-09-28 2017-10-24 Федеральное государственное бюджетное научное учреждение "СЕВЕРО-КАВКАЗСКИЙ ЗОНАЛЬНЫЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ВЕТЕРИНАРНЫЙ ИНСТИТУТ" (ФГБНУ СКЗНИВИ) Способ стимуляции иммунного ответа и препарат для его осуществления
WO2019108928A1 (en) * 2017-11-30 2019-06-06 Ohio State Innovation Foundation Mucoadhesive nanoparticle entrapped influenza virus vaccine delivery system
EP4135519B1 (en) * 2020-04-16 2024-09-25 Bayer Aktiengesellschaft Active compound combinations and fungicide compositions comprising those
PL4135520T3 (pl) * 2020-04-16 2025-02-17 Bayer Aktiengesellschaft Kombinacje związków aktywnych i kompozycje grzybobójcze je zawierające
WO2021209364A1 (en) * 2020-04-16 2021-10-21 Bayer Aktiengesellschaft Active compound combinations and fungicide compositions comprising those
CN112063699B (zh) * 2020-09-16 2021-06-18 成都市疾病预防控制中心 一种用于研究hiv感染者免疫衰老机制的系统
US20250177515A1 (en) * 2022-01-10 2025-06-05 The Children's Medical Center Corporation Methods and compositions relating to immunization of immune distinct patients

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9602280D0 (sv) 1996-06-10 1996-06-10 Pharmatrix Ab Immunstimulerande lipidformulering
SE9900496D0 (sv) 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine formulation
US8410248B2 (en) 1999-03-12 2013-04-02 Human Genome Sciences Inc. HWBAO62 polypeptides
US20030072764A1 (en) 2001-04-05 2003-04-17 O'hagan Derek Mucosal boosting following parenteral priming
US20050208602A1 (en) 2001-08-10 2005-09-22 Rosen Craig A 89 human secreted proteins
WO2004042000A2 (en) 2002-05-17 2004-05-21 Human Genome Sciences, Inc. 157 human secreted proteins
WO2004047862A1 (en) 2002-11-26 2004-06-10 Eurocine Ab Novel amine-based adjuvant
CN103446582A (zh) 2003-08-11 2013-12-18 财团法人阪大微生物病研究会 包含诱导粘膜免疫的佐剂的新型疫苗
AU2006247188A1 (en) 2005-05-18 2006-11-23 Children's Hospital & Research Center At Oakland Methods and compositions for immunizing against chlamydia infection
CN101213199B (zh) 2005-06-30 2013-12-18 卫材R&D管理有限公司 用于制备免疫佐剂的化合物
CN101257919B (zh) 2005-08-05 2012-08-29 国立大学法人德岛大学 可以由选择性产生IgA抗体向产生IgA和IgG两种抗体转换的抗原药物载体和使用该载体的经鼻·粘膜疫苗
RU2323742C1 (ru) * 2007-02-15 2008-05-10 Государственное учреждение Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова (ГУ НИИВС им. И.И. Мечникова) Способ повышения иммуногенности инактивированной гриппозной вакцины
WO2009071633A1 (en) * 2007-12-06 2009-06-11 Glaxosmithkline Biologicals S.A. Influenza composition
EP2293813A4 (en) 2008-05-23 2012-07-11 Univ Michigan NANO EMULSION VACCINES
AU2009293595A1 (en) 2008-05-23 2010-03-25 The Regents Of The University Of Michigan Nanoemulsion adjuvants
US20130178383A1 (en) 2008-11-12 2013-07-11 David Spetzler Vesicle isolation methods
KR101704988B1 (ko) 2009-05-28 2017-02-08 큐알엔에이, 인크. 항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료
EP2621524A1 (en) 2010-09-30 2013-08-07 Eurocine Vaccines AB Improved vaccine compositions

Also Published As

Publication number Publication date
CN104884085A (zh) 2015-09-02
BR112015014243A2 (pt) 2017-07-11
RU2661408C2 (ru) 2018-07-16
BR112015014243A8 (pt) 2019-10-08
JP2016502997A (ja) 2016-02-01
AU2013360890A1 (en) 2015-07-02
KR20210007042A (ko) 2021-01-19
JP2019112448A (ja) 2019-07-11
EP3431101A1 (en) 2019-01-23
AU2013360889B2 (en) 2016-12-01
HK1212611A1 (zh) 2016-06-17
US20150306205A1 (en) 2015-10-29
MX2015007688A (es) 2015-09-07
RU2661407C2 (ru) 2018-07-16
CN112826929A (zh) 2021-05-25
WO2014095944A1 (en) 2014-06-26
AU2013360889A1 (en) 2015-07-02
WO2014095943A1 (en) 2014-06-26
CA2895023A1 (en) 2014-06-26
RU2015129077A (ru) 2017-01-23
JP2016502996A (ja) 2016-02-01
AU2013360890B2 (en) 2017-04-13
BR112015014174A2 (pt) 2017-07-11
HK1213492A1 (zh) 2016-07-08
EP2931308B1 (en) 2018-10-10
AU2013360889C1 (en) 2017-06-08
EP2931307A1 (en) 2015-10-21
EP2742952A1 (en) 2014-06-18
CN104870010A (zh) 2015-08-26
MX2015007753A (es) 2016-01-08
KR20150132093A (ko) 2015-11-25
EP2931307B1 (en) 2018-09-12
EP2931308A1 (en) 2015-10-21
RU2015129028A (ru) 2017-01-23
US11065325B2 (en) 2021-07-20
CA2895028A1 (en) 2014-06-26
US20150306204A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
AU2013360889B2 (en) Vaccine composition for naive subjects
KR101696727B1 (ko) 인플루엔자 백신
KR20140069379A (ko) 인플루엔자 백신
JP2009209086A (ja) 粘膜投与型ワクチン
JP2011057605A (ja) 粘膜投与型ワクチン
JP5918870B2 (ja) インフルエンザに対する改善されたワクチン接種
Maltais et al. Intranasally administered Endocine™ formulated 2009 pandemic influenza H1N1 vaccine induces broad specific antibody responses and confers protection in ferrets
US8535683B2 (en) Intranasal or inhalational administration of virosomes
US20240398930A1 (en) A vaccine for coronavirus and influenza virus, and method for preparation thereof
KR20090016659A (ko) 비로좀을 기제로 한 비강내 인플루엔자 백신
US20080038294A1 (en) Intranasal or inhalational administration of virosomes
Willis The Effect of Maternal Antibodies on Anti-viral Immunity in Infant Mice
HK1128077B (en) Intranasal influenza vaccine based on virosomes
HK1128077A1 (en) Intranasal influenza vaccine based on virosomes
HK1170418A (en) Intranasal influenza vaccine based on virosomes

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150717

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20181214

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200424

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20201008

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200424

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210111